ID   PT45-P1res
AC   CVCL_8409
DR   cancercelllines; CVCL_8409
DR   Wikidata; Q54948656
RX   PubMed=16474845;
CC   Selected for resistance to: ChEBI; CHEBI_4911; Etoposide (VP-16).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8408 ! PT45-P1
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=16474845; DOI=10.1038/sj.onc.1209423;
RA   Sebens Muerkoster S., Lust J., Arlt A., Hasler R., Witt M., Sebens T.,
RA   Schreiber S., Folsch U.R., Schafer H.;
RT   "Acquired chemoresistance in pancreatic carcinoma cells: induced
RT   secretion of IL-1beta and NO lead to inactivation of caspases.";
RL   Oncogene 25:3973-3981(2006).
//